News

The adjustments come after the company announced a reprioritization to focus on ALLOB in September 2021.

There were not enough data at 6 months to predict expanded disability status scale (EDSS) improvements after treatment.

AVROBIO decided to deprioritize their Fabry disease gene therapy program in January 2022.

After submitting an amended IND, Adverum’s gene therapy is set to be evaluated in the phase 2 LUNA trial.

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed mutations the Parkinson’s Foundation has identified.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Verve Therapeutics is currently conducting a clinical trial in New Zealand and expects to be able to open trials in the UK and US later in 2022.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the foundation’s mission.

SCG101 will be evaluated in trials across China, Singapore, and the US.

A second cohort has been dosed with 7.7e11 vg/kg to hopefully confirm the dose for phase 3 trials.

A phase 1 trial has completed enrollment in its first cohort and is now enrolling the second.

Foundation Fighting Blindness is helping to support the development of gene therapies for retinal diseases.

The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.

Legend Biotech seeks to prioritize other product candidates in its pipeline.

Myrtelle’s rAAV-Olig001-ASPA was granted fast track, rare pediatric disease, and orphan drug designations in March 2022.

The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.

The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.

The FDA has lifted a clinical hold on the trial of VX880 placed in May 2022 due to insufficient information.

The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.

MUSC recently launched In Your DNA SC, a 4-year study to collect and glean insights from genetic testing in the general population.

The global head of research and development at Atara Biotherapeutics discussed ATA188 ahead of anticipated data readouts this month.

The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.

Review top news and interview highlights from the week ending July 1, 2022.

A patient showed more than a 50% reduction in N-acetylaspartate (NAA) in brain white matter at 3 months post-treatment.

The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.

ADVM-022 was also granted PRIME designation by the EMA on June 24, 2022.